- Case Report
Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation
- Shangxin Yang,
- Ashrit Multani,
- Jacob M. Garrigues,
- Michael S. Oh,
- Peera Hemarajata,
- Taylor Burleson,
- Nicole M. Green,
- Caspian Oliai,
- Pryce T. Gaynor and
- Omer E. Beaird
- + 3 authors
Remdesivir is the first FDA-approved drug for treating severe SARS-CoV-2 infection and targets RNA-dependent RNA polymerase (RdRp) that is required for viral replication. To monitor for the development of mutations that may result in remdesivir resis...

